Leiner Suspends U.S. OTC Operations, Expects Perrigo To Meet Demand
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products expects to lose business to competing private-labeler Perrigo following the voluntary suspension of its U.S. OTC operations